AB102 / Arcus Biosciences - LARVOL DELTA

The Novel Molecule AB102 Potently Inhibits MRGPRX2-Dependent Mast Cell Activation and Disease-Relevant Gene Transcription (EADV 2026) - "Consistent with these molecular effects, oral AB102 significantly reduced substance P- and icatibant-induced acute paw swelling and prevented ciprofloxacin-induced systemic anaphylaxis in human MRGPRX2 KI mice. Conclusions AB102 is a potent and selective MRGPRX2 antagonist that suppresses the activation of disease-enriched signature genes and blocks mast cell driven responses in vitro and in vivo . These findings provide strong preclinical support for the therapeutic potential of AB102 in mast cell-mediated disorders, including AD and CSU."

Atopic Dermatitis • Chronic Spontaneous Urticaria • Dermatitis • Dermatology • Inflammation • Urticaria

A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants (clinicaltrials.gov) - P1 | N=130 | Recruiting | Sponsor: Arcus Biosciences, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human

A Phase 1, First-in-human Single Photon Emission Computed Tomography (SPECT) Imaging Study to Assess [203Pb]Pb-AB102 in Participants with Advanced Solid Tumours (ANZCTR) - P1 | N=10 | Not yet recruiting | Sponsor: ARTBIO Pty Ltd

First-in-human • New P1 trial • Breast Cancer • Head and Neck Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer

A proof-of-concept study evaluating AB102 as a potential oral therapy for patients with chronic spontaneous urticaria is expected in mid-2027. (Businesswire)

New trial • Chronic Spontaneous Urticaria • Immunology

A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants (clinicaltrials.gov) - P1 | N=130 | Not yet recruiting | Sponsor: Arcus Biosciences, Inc.

First-in-human • New P1 trial